I Squared Capital has closed the ISQ Global Infrastructure Fund III at its USD15 billion legal cap, exceeding an initial target of USD12 billion. Including commitments from I Squared Capital and a dedicated co-investment vehicle, the fund has USD15.5 billion in investable capital and received commitments from over 200 institutional investors, including public and private pensions, sovereign funds, insurance companies, asset managers and family offices in 27 countries.  I Squared Capital has targeted the deployment of approximately 36 per cent of the fund in ten investments across its targeted sectors.

AmerisourceBergen, a healthcare solutions company, has launched AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally. AB Health Ventures will build on AmerisourceBergen’s ongoing commitment to delivering innovation for its customers. AB Health Ventures will initially launch with USD150 million allocated for investment in early-to mid-stage health-related startups around the world. The fund will prioritise investments in entrepreneurs who are pursuing bold ideas in areas such as the future of pharmacy and distribution, clinical development and commercialisation of pharmaceuticals, practice

Lead Edge Capital (LEC), a technology-focused growth stage investment fund, has closed Fund VI, which was oversubscribed, with over USD1.95 billion of commitments from Lead Edge’s network of over 500 limited partners and institutions. LEC will target making equity investments of between USD15 million and USD200 million per portfolio company from Fund VI and continue its focus on investing primarily in private companies, with a flexible mandate that also enables public company investments. The addition of Fund VI brings the firm’s total capital raised since inception to USD5 billion. LEC’s Limited Partners come from companies including Charles Schwab, Capital One,

Global alternative investment manager Ares Management Corporation (Ares), has launched the Ares Private Markets Fund, a new registered, continuously offered, non-traded, closed-end fund that intends to invest in an actively managed portfolio of private equity and other private assets principally through secondary market fund investments, and, to a lesser degree, primary fund investments and direct co-investments. The Fund has been launched with more than USD250 million in initial capital, including investments from two significant institutional investors as well as a USD75 million investment directly from Ares. Leveraging the strength of the global Ares platform and the depth of Ares’ Secondary

Global investment firm Carlyle has made the final close of its second Carlyle Credit Opportunities Fund (CCOF II) which raised USD4.6 billion, hitting its hard cap, exceeding its USD3.5 billion target, and attracting almost double the amount raised for its predecessor fund. Including available leverage, investable capital is approximately USD6 billion.   CCOF II provides capital solutions to companies seeking an alternative to traditional capital markets or private equity. Its directly originated solutions are targeted at upper middle market borrowers, including family and entrepreneur-owned businesses, sponsor-backed companies and asset-backed borrowers.     CCOF II has already committed approximately USD3.8 billion—or 6

Ares Management Corporation (Ares), a global alternative investment manager, has launched the Ares Private Markets Fund (the Fund), a new registered, continuously offered, non-traded, closed-end fund that intends to invest in an actively managed portfolio of private equity and other private assets. It will principally invest through secondary market fund investments, and, to a lesser degree, primary fund investments and direct co-investments.  The Fund has been launched with more than USD250 million in initial capital, including investments from two significant institutional investors as well as a USD75 million investment directly from Ares.    The Fund will be distributed through Ares

British VC JamJar Investments has raised a fund of over GBP100 million from institutional investors, founders and via a crowdfund to expand their ability to back early-stage consumer brands across the UK and Europe. This includes a cornerstone commitment of GBP48 million from the British Business Bank’s Enterprise Capital Funds (ECF) programme, making JamJar the largest ECF to date. This second fund, the first institutionally backed fund for JamJar, will solidify their position as the UK’s leading consumer fund and allow them to invest in and support an even greater number of ambitious founders. The JamJar partners are once again

Kempen European Private Equity Fund II, the private equity fund managed by Van Lanschot Kempen has closed with total committed capital of EUR245 million, the fund’s maximum target size. The Private Markets team at Van Lanschot Kempen manages assets based on three strategies and since its start in the summer of 2017, has accumulated assets under management of around EUR1.2 billion. One of the funds that it manages, Kempen European Private Equity Fund II is aimed at the small to mid-market segment of the European buy-out private equity market. It is a hybrid investment fund that combines investments in private

HEAL Partners, an Australia and Cayman based global growth and follow-on fund specialising in health, education and lifestyle (HEAL) sector investments, has signed a Strategic Relationship Agreement with affiliates of Elliott Investment Management (Elliott). HEAL will launch its USD350-500 million Fund II in H1 2022. As part of the Strategic Relationship, Elliott is expected to contribute a significant anchor commitment to the fund. This Strategic Relationship follows Elliott’s January 2021 investment in Removery, the world’s largest tattoo removal business and a HEAL portfolio company founded by HEAL Partners’ Mark Evans, Chris Chambers and Peter Chapman. Headquartered in Austin, Texas, Removery